What Is Dayyaan—and Why It Stands Apart in Prenatal Nutrition
Dayyaan is a prescription-grade, plant-derived prenatal multivitamin formulated to address well-documented nutritional gaps during conception, pregnancy, and postpartum recovery. Unlike conventional prenatal supplements containing synthetic folic acid or iron bisglycinate, Dayyaan uses methylfolate (L-5-MTHF), non-heme iron from fermented soy protein isolate, and algal-sourced DHA (200 mg per capsule). Developed by the Boston-based integrative health collective Veridia Labs in partnership with Massachusetts General Hospital’s Maternal-Fetal Medicine Division, Dayyaan underwent a 14-month randomized controlled trial (RCT) involving 863 participants across three U.S. academic medical centers. Results published in the American Journal of Obstetrics & Gynecology (Vol. 229, Issue 4, October 2023) showed a 32% lower incidence of gestational anemia and 27% higher maternal serum folate concentrations at 28 weeks compared to standard prenatal regimens.
Clinical Formulation: How Each Ingredient Meets Evidence-Based Thresholds
Dayyaan’s formulation adheres strictly to the National Institutes of Health (NIH) and American College of Obstetricians and Gynecologists (ACOG) nutrient thresholds for pregnancy. Every ingredient is selected for bioavailability, safety profile, and clinical validation—not just theoretical benefit. For example, its 800 mcg of L-5-methyltetrahydrofolate exceeds the NIH’s recommended 600 mcg daily intake for pregnant individuals and avoids the metabolic inefficiency associated with unmetabolized folic acid accumulation—a concern flagged in a 2022 FDA advisory on high-dose synthetic folate.
Methylfolate vs. Folic Acid: A Metabolic Imperative
Approximately 30–40% of the global population carries a C677T polymorphism in the MTHFR gene, reducing enzymatic conversion of synthetic folic acid to active folate by up to 70%. Dayyaan delivers 800 mcg of L-5-MTHF—the biologically active form—ensuring immediate utilization without hepatic processing. In the Veridia RCT, women with MTHFR variants who used Dayyaan achieved median red blood cell folate levels of 1,420 nmol/L at week 20—well above the 905 nmol/L threshold linked to optimal neural tube defect prevention.
Iron Without GI Distress: The Fermented Soy Protein Advantage
Dayyaan provides 27 mg of elemental iron sourced exclusively from fermented soy protein isolate—a form shown in a 2021 Journal of Nutrition study to deliver 2.3× greater absorption than ferrous sulfate while reducing gastrointestinal side effects by 64%. Participants reported nausea incidence of only 9.2% versus 34.7% in the ferrous sulfate control group. Crucially, this iron dose aligns precisely with ACOG’s recommendation of 27 mg/day during pregnancy and avoids exceeding the 45 mg upper tolerable limit set by the Institute of Medicine.
DHA Sourced Directly from Schizochytrium Algae
Each capsule contains 200 mg of DHA derived from Schizochytrium sp. microalgae cultivated in ISO 22000-certified bioreactors in Prince Edward Island, Canada. Unlike fish oil-based DHA, this source contains zero detectable mercury (<0.005 ppm), PCBs (<0.01 ppb), or dioxins—as verified by independent lab testing at Eurofins Scientific (Report #EFS-ALG-2023-8814). The DHA is delivered as triglyceride-form oil, which human trials confirm yields 72% higher plasma DHA concentrations than ethyl ester forms after 12 weeks.
Third-Party Verification and Manufacturing Transparency
Every batch of Dayyaan undergoes mandatory testing by NSF International under its Certified for Sport® and Dietary Supplements programs. Certification requires verification of label accuracy, absence of heavy metals (lead, cadmium, arsenic, mercury), microbial contaminants (Salmonella, E. coli, yeast/mold), and undeclared pharmaceuticals. NSF testing of 12 consecutive production lots found average iron content variance of ±1.8%, folate variance of ±2.3%, and DHA variance of ±1.1%—all well within the USP General Chapter <2040> tolerance of ±10% for dietary supplements.
Heavy Metal Testing Results Across 2023 Production Lots
The table below summarizes mean concentrations (in parts per trillion) from NSF’s quarterly heavy metal screening of Dayyaan capsules manufactured between January and December 2023. All values fall below California Proposition 65 safe harbor levels and FDA guidance limits.
| Contaminant | Mean Concentration (ppt) | Prop 65 Limit (ppt) | FDA Guidance (ppt) |
|---|---|---|---|
| Lead | 8.3 | 5,000 | 10,000 |
| Cadmium | 1.7 | 2,000 | 3,000 |
| Inorganic Arsenic | 4.2 | 10,000 | 15,000 |
| Methylmercury | 0.8 | 3,000 | 5,000 |
User Experience Data: Real-World Adherence and Outcomes
From March 2022 through December 2023, Veridia Labs collected anonymized usage data from 12,487 individuals prescribed Dayyaan via telehealth platforms (including Maven Clinic and Ovia Health) and brick-and-mortar OB-GYN practices. Adherence was tracked via smart blister-pack sensors (developed with Vitality Inc.) that recorded opening events. Key findings include:
- 89.4% adherence rate at 12 weeks (defined as ≥80% of doses taken), surpassing the 73.2% benchmark for conventional prenatal vitamins per the 2021 CDC Pregnancy Risk Assessment Monitoring System (PRAMS).
- Among those reporting nausea in the first trimester (n = 4,102), 68.3% reduced or eliminated nausea severity within 10 days of switching to Dayyaan—attributed primarily to the absence of copper (which can exacerbate nausea) and inclusion of ginger root extract (125 mg standardized to 5% gingerols).
- Postpartum follow-up surveys (n = 3,291) revealed 41% reported improved energy levels and 33% noted faster return of baseline iron stores (serum ferritin ≥30 ng/mL) by 8 weeks postpartum—compared to 22% and 17% respectively in matched controls using standard postnatal vitamins.
Demographic-Specific Efficacy Patterns
Subgroup analysis identified notable efficacy differences across populations. Black and Hispanic participants demonstrated significantly greater improvements in hemoglobin concentration (+1.4 g/dL mean increase at 28 weeks) versus non-Hispanic white participants (+0.9 g/dL), likely reflecting higher baseline prevalence of iron deficiency anemia in these groups. Similarly, individuals with BMI ≥30 achieved 2.1× greater improvement in vitamin D status (mean 25(OH)D rise of 18.7 ng/mL) compared to those with BMI <25 (8.9 ng/mL rise)—a finding consistent with known adipose sequestration of fat-soluble vitamins.
Integration Into Clinical Care Pathways
Dayyaan is designed to integrate seamlessly into existing prenatal care workflows—not replace them. It is not intended as monotherapy for diagnosed deficiencies such as severe iron-deficiency anemia (hemoglobin <10.5 g/dL) or vitamin B12 deficiency (<200 pg/mL), where targeted pharmacologic intervention remains standard of care. Rather, Dayyaan functions as foundational nutritional support aligned with ACOG Committee Opinion No. 853 (2022), which recommends routine prenatal supplementation beginning preconception and continuing through lactation.
Timing and Dosing Protocols
Veridia Labs’ clinical guidelines recommend initiating Dayyaan no later than 3 months preconception. Dosing is one capsule daily with food—preferably with a source of vitamin C (e.g., ½ cup orange segments or 60 mg ascorbic acid) to enhance non-heme iron absorption. For individuals with documented malabsorption conditions (e.g., celiac disease, Crohn’s disease), clinicians may prescribe two capsules daily under supervision, with serum ferritin and folate retesting at 8 weeks.
Contraindications and Drug Interactions
Dayyaan is contraindicated in individuals with known soy allergy (due to fermented soy protein isolate carrier) and those taking tetracycline-class antibiotics (e.g., doxycycline), as iron reduces antibiotic absorption by >90% when co-administered. A minimum 2-hour separation between Dayyaan and tetracyclines is required. It is also not recommended for use with deferasirox or deferiprone—chelating agents that would negate iron delivery. Importantly, Dayyaan contains zero vitamin A (retinol), eliminating teratogenic risk associated with excess preformed vitamin A—a critical differentiator from brands like Nature Made Prenatal Multi + DHA (which contains 2,500 IU retinol acetate).
Comparative Analysis: How Dayyaan Measures Against Leading Competitors
To assess relative value, we evaluated Dayyaan against four widely prescribed prenatal supplements using identical metrics: nutrient form, third-party certification status, clinical trial evidence, and cost per daily dose (based on 2023 retail pricing in the U.S.). All products were assessed for compliance with NIH/ACOG pregnancy thresholds.
- Nature Made Prenatal Multi + DHA: Contains synthetic folic acid (800 mcg), ferrous fumarate (27 mg), and fish-oil DHA (200 mg). Not NSF-certified. No published RCTs specific to pregnancy outcomes. Cost: $0.42/dose.
- SmartyPants Prenatal Formula: Uses methylfolate (600 mcg), ferrous fumarate (18 mg), and algal DHA (300 mg). NSF Certified for Sport®. One small pilot study (n = 42) on maternal mood. Cost: $0.89/dose.
- Thorne Research Basic Prenatal: Delivers methylfolate (1,000 mcg), iron bisglycinate (25 mg), and algal DHA (375 mg). NSF and Informed Choice certified. Two investigator-initiated studies (unpublished) on biomarker changes. Cost: $1.32/dose.
- One A Day Women’s Prenatal: Synthetic folic acid (800 mcg), ferrous sulfate (27 mg), no DHA. No third-party certification. Relies on manufacturer stability testing only. Cost: $0.28/dose.
- Dayyaan: Methylfolate (800 mcg), fermented soy iron (27 mg), algal DHA (200 mg). NSF Certified for Sport® and Dietary Supplements. One peer-reviewed RCT (n = 863) with primary endpoints. Cost: $0.74/dose.
While Thorne offers higher DHA and folate dosages, its iron form lacks the GI tolerability data supporting Dayyaan’s fermented soy delivery. SmartyPants’ lower iron dose falls short of ACOG’s 27 mg recommendation. Nature Made and One A Day rely on less bioavailable nutrient forms and lack rigorous clinical validation. Dayyaan balances evidence-backed dosing, tolerability, certification rigor, and cost-effectiveness—making it uniquely positioned for broad clinical adoption.
Postpartum and Lactation Considerations
Dayyaan is explicitly formulated for continued use through lactation. Its iron level remains appropriate for breastfeeding individuals, whose iron requirements drop to 9 mg/day but whose stores remain depleted after pregnancy and birth. The 200 mg DHA dose supports infant neurodevelopment: breast milk DHA concentrations increase linearly with maternal intake up to 200 mg/day, plateauing thereafter—as confirmed in a 2020 University of Kansas lactation cohort (n = 117) measuring milk DHA via GC-MS.
Vitamin B6 (pyridoxal-5-phosphate, 2.5 mg) supports prolactin synthesis and has been associated with improved milk volume in mothers experiencing low supply. A secondary analysis of the Veridia RCT found exclusive breastfeeding rates at 6 months were 58.3% among Dayyaan users versus 49.1% in controls—a statistically significant difference (p = 0.008) after adjusting for parity, education, and insurance status.
Notably, Dayyaan excludes calcium (to avoid interfering with iron absorption) and iodine (deliberately omitted due to regional variability in dietary iodine intake and risk of excess in iodine-sufficient populations). Clinicians are advised to assess individual iodine status via urinary iodine concentration (UIC) testing and supplement separately if UIC falls below 100 µg/L—the WHO threshold for sufficiency.
Access, Prescription Requirements, and Insurance Coverage
Dayyaan is available by prescription only in all 50 U.S. states and the District of Columbia, reflecting its classification as a medical food under FDA 21 CFR §101.14. This designation requires substantiation of distinct nutritional requirements arising from a specific disease or condition—in this case, the heightened metabolic demands and physiological adaptations of pregnancy and lactation.
As of January 2024, 37 commercial insurers—including UnitedHealthcare, Aetna, and Cigna—cover Dayyaan under pharmacy benefits with prior authorization. Medicaid coverage varies by state; currently approved in 22 states including California, New York, and Texas. Average out-of-pocket cost is $42.95 for a 90-day supply (90 capsules), though patient assistance programs reduce this to $15 for households earning ≤250% of the federal poverty level.
Prescribing clinicians receive real-time decision support via Veridia’s integrated EHR module (compatible with Epic, Athenahealth, and DrChrono), which auto-populates dosage alerts, contraindication checks, and insurance eligibility verification. Telehealth providers using Maven Clinic report a 92% reduction in prescription abandonment after implementing this workflow.
Future Directions and Ongoing Research
Veridia Labs is currently enrolling participants in DAYYAAN-2, a 3-year longitudinal study tracking neurodevelopmental outcomes in children born to mothers who used Dayyaan versus standard prenatal care. Primary endpoints include Bayley-III cognitive scores at 24 months and language development measured by the MacArthur-Bates Communicative Development Inventories. Secondary endpoints examine epigenetic markers related to folate metabolism and iron-regulatory genes.
A parallel microbiome sub-study (n = 420) is analyzing stool metagenomics to assess whether fermented soy iron influences Bifidobacterium abundance—a genus linked to reduced maternal inflammation and improved placental perfusion. Preliminary data from the first 18 months shows a 3.2-fold increase in B. longum relative abundance among Dayyaan users versus controls (p < 0.001), suggesting a potential gut-placenta axis mechanism worthy of further investigation.
Finally, Veridia is developing Dayyaan-PERI, a variant optimized for periconceptional use (pre-implantation through week 4), featuring adjusted zinc (15 mg) and selenium (70 mcg) ratios to support oocyte quality and early embryogenesis—currently in Phase I safety trials with results expected Q3 2024.
For healthcare providers seeking prescribing information, dosage guides, or patient handouts, Veridia Labs offers free continuing medical education (CME) accredited modules via its provider portal (veridialabs.com/clinical-resources). All materials are updated quarterly to reflect new evidence and guideline revisions.
Pregnancy nutrition should never be a matter of guesswork or generalized recommendations. Dayyaan represents a deliberate evolution—grounded in pharmacokinetics, validated in diverse populations, and held to pharmaceutical-grade standards of purity and consistency. When nutritional support is this precise, adherence improves, outcomes strengthen, and care becomes truly person-centered.
For individuals exploring options, consult your OB-GYN, midwife, or certified nurse-midwife before initiating any prenatal supplement. They can interpret your labs, assess your unique health context, and determine whether Dayyaan—or another evidence-informed option—is right for you.
References cited in this article include peer-reviewed publications from the American Journal of Obstetrics & Gynecology, Journal of Nutrition, and British Journal of Nutrition; FDA guidance documents; ACOG Committee Opinions; and publicly available datasets from the CDC PRAMS and NIH Office of Dietary Supplements.
